Tetsuro Ohmori

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1054317/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Peritraumatic reactions, PTSD symptoms, and painâ€: A study of train disasters in Japan. Journal of Medical Investigation, 2021, 68, 85-89.	0.2	1
2	Optimized protocol for the extraction of RNA and DNA from frozen whole blood sample stored in a single EDTA tube. Scientific Reports, 2021, 11, 17075.	1.6	6
3	An attempt to analyze the longitudinal psychological state of cancer patients in the active treatment stage. Journal of Medical Investigation, 2021, 68, 148-153.	0.2	0
4	Structural variation in the glycogen synthase kinase 3β and brainâ€derived neurotrophic factor genes in Japanese patients with bipolar disorders. Neuropsychopharmacology Reports, 2020, 40, 46-51.	1.1	3
5	Decelerated epigenetic aging associated with mood stabilizers in the blood of patients with bipolar disorder. Translational Psychiatry, 2020, 10, 129.	2.4	41
6	Predictors of life skills in people with schizophrenia. Journal of Medical Investigation, 2020, 67, 75-82.	0.2	0
7	Plasma levels of matrix metalloproteinaseâ€9 (MMPâ€9) are associated with cognitive performance in patients with schizophrenia. Neuropsychopharmacology Reports, 2020, 40, 150-156.	1.1	15
8	ABCA7 Gene Expression and Genetic Association Study in Schizophrenia. Neuropsychiatric Disease and Treatment, 2020, Volume 16, 441-446.	1.0	3
9	Behavioral and psychological symptoms of dementia (BPSD) and care burden : Examination in the facility staff forAelderly residents. Journal of Medical Investigation, 2020, 67, 236-239.	0.2	3
10	<p>Negative and positive self-thoughts predict subjective quality of life in people with schizophrenia</p> . Neuropsychiatric Disease and Treatment, 2019, Volume 15, 293-301.	1.0	15
11	<p>Clinical factors influencing resilience in patients with anorexia nervosa</p> . Neuropsychiatric Disease and Treatment, 2019, Volume 15, 391-395.	1.0	5
12	Epigenetic clock analysis of blood samples from Japanese schizophrenia patients. NPJ Schizophrenia, 2019, 5, 4.	2.0	37
13	Increased serum levels and promoter polymorphisms of macrophage migration inhibitory factor in schizophrenia. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2018, 83, 33-41.	2.5	17
14	Plasma Levels of Soluble Tumor Necrosis Factor Receptor 2 (sTNFR2) Are Associated with Hippocampal Volume and Cognitive Performance in Patients with Schizophrenia. International Journal of Neuropsychopharmacology, 2018, 21, 631-639.	1.0	16
15	Relationship between social and cognitive functions in people with schizophrenia. Neuropsychiatric Disease and Treatment, 2018, Volume 14, 2215-2224.	1.0	15
16	Comparative Analyses of Copy-Number Variation in Autism Spectrum Disorder and Schizophrenia Reveal Etiological Overlap and Biological Insights. Cell Reports, 2018, 24, 2838-2856.	2.9	177
17	Elevated peripheral blood glutamate levels in major depressive disorder. Neuropsychiatric Disease and Treatment, 2018, Volume 14, 945-953.	1.0	40
18	Effect of cognitive function on jumping to conclusion in patients with schizophrenia. Schizophrenia Research: Cognition, 2018, 12, 50-55.	0.7	10

TETSURO OHMORI

#	Article	IF	CITATIONS
19	Longer telomeres in elderly schizophrenia are associated with long-term hospitalization in the Japanese population. Journal of Psychiatric Research, 2018, 103, 161-166.	1.5	12
20	Structural equation modeling approach between salience network dysfunction, depressed mood, and subjective quality of life in schizophrenia: an ICA resting-state fMRI study. Neuropsychiatric Disease and Treatment, 2018, Volume 14, 1585-1597.	1.0	11
21	Mitochondrial DNA copy number of peripheral blood in bipolar disorder: The present study and a meta-analysis. Psychiatry Research, 2018, 269, 115-117.	1.7	39
22	Decreased serum pyridoxal levels in schizophrenia: meta-analysis and Mendelian randomization analysis. Journal of Psychiatry and Neuroscience, 2018, 43, 194-200.	1.4	27
23	De novo non-synonymous TBL1XR1 mutation alters Wnt signaling activity. Scientific Reports, 2017, 7, 2887.	1.6	19
24	Influence of cognitive function on quality of life in anorexia nervosa patients. Psychiatry and Clinical Neurosciences, 2017, 71, 328-335.	1.0	7
25	Altered KYN/TRP, Gln/Glu, and Met/methionine sulfoxide ratios in the blood plasma of medication-free patients with major depressive disorder. Scientific Reports, 2017, 7, 4855.	1.6	39
26	Effect of Clozapine on DNA Methylation in Peripheral Leukocytes from Patients with Treatment-Resistant Schizophrenia. International Journal of Molecular Sciences, 2017, 18, 632.	1.8	49
27	Gene expression-based biological test for major depressive disorder: an advanced study. Neuropsychiatric Disease and Treatment, 2017, Volume 13, 535-541.	1.0	5
28	Prefrontal cortex activation during neuropsychological tasks might predict response to pharmacotherapy in patients with obsessive–compulsive disorder. Neuropsychiatric Disease and Treatment, 2017, Volume 13, 577-583.	1.0	6
29	Elevated TREM2 mRNA expression in leukocytes in schizophrenia but not major depressive disorder. Journal of Neural Transmission, 2016, 123, 637-641.	1.4	13
30	Association study of polymorphism in the serotonin transporter gene promoter, methylation profiles, and expression in patients with major depressive disorder. Human Psychopharmacology, 2016, 31, 193-199.	0.7	35
31	Low methylation rates of dopamine receptor D2 gene promoter sites in Japanese schizophrenia subjects. World Journal of Biological Psychiatry, 2016, 17, 449-456.	1.3	20
32	Prefrontal activation during two Japanese Stroop tasks revealed with multi-channel near-infrared spectroscopy. Journal of Medical Investigation, 2015, 62, 51-55.	0.2	5
33	Polymorphism in the promoter of the gene for the serotonin transporter affects the age of onset of major depressive disorder in the Japanese population. Journal of Affective Disorders, 2015, 183, 156-158.	2.0	8
34	Blood diagnostic biomarkers for major depressive disorder using multiplex DNA methylation profiles: discovery and validation. Epigenetics, 2015, 10, 135-141.	1.3	70
35	Biological tests for major depressive disorder that involve leukocyte gene expression assays. Journal of Psychiatric Research, 2015, 66-67, 1-6.	1.5	31
36	Association of autism tendency and hemodynamic changes in the prefrontal cortex during facial expression stimuli measured by multiâ€channel nearâ€infrared spectroscopy. Psychiatry and Clinical Neurosciences, 2015, 69, 145-152.	1.0	14

TETSURO OHMORI

#	Article	IF	CITATIONS
37	TREM2 mRNA Expression in Leukocytes Is Increased in Alzheimer's Disease and Schizophrenia. PLoS ONE, 2015, 10, e0136835.	1.1	31
38	Meta-analyses of Blood Homocysteine Levels for Gender and Genetic Association Studies of the MTHFR C677T Polymorphism in Schizophrenia. Schizophrenia Bulletin, 2014, 40, 1154-1163.	2.3	88
39	Microarray analysis of global gene expression in leukocytes following lithium treatment. Human Psychopharmacology, 2014, 29, 190-198.	0.7	20
40	Neuropsychological and psychiatric assessments following bilateral deep brain stimulation of the subthalamic nucleus in Japanese patients with Parkinson's disease. Journal of Clinical Neuroscience, 2014, 21, 1595-1598.	0.8	17
41	Missense variants of the alanine:glyoxylate aminotransferase 2 gene are not associated with Japanese schizophrenia patients. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2014, 53, 137-141.	2.5	6
42	Changes in plasma d-serine, l-serine, and glycine levels in treatment-resistant schizophrenia before and after clozapine treatment. Neuroscience Letters, 2014, 582, 93-98.	1.0	50
43	<scp>M</scp> easurement and <scp>T</scp> reatment <scp>R</scp> esearch to <scp>I</scp> mprove <scp>C</scp> ognition in <scp>S</scp> chizophrenia <scp>C</scp> onsensus <scp>C</scp> ognitive <scp>B</scp> attery: <scp>V</scp> alidation of the <scp>J</scp> apanese version. Psychiatry and Clinical Neurosciences 2013 67, 182-188	1.0	34
44	Multiâ€channel nearâ€infrared spectroscopy shows reduced activation in the prefrontal cortex during facial expression processing in pervasive developmental disorder. Psychiatry and Clinical Neurosciences, 2012, 66, 26-33.	1.0	16
45	Quality of life and cognitive dysfunction in people with schizophrenia. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2011, 35, 53-59.	2.5	56
46	Common coding variant in the TCF7L2 gene and study of the association with type 2 diabetes in Japanese subjects. Journal of Human Genetics, 2008, 53, 972-982.	1.1	7
47	Predictors of subjective and objective quality of life in outpatients with schizophrenia. Psychiatry and Clinical Neurosciences, 2008, 62, 404-411.	1.0	76
48	Subjective and objective quality of life, levels of life skills, and their clinical determinants in outpatients with schizophrenia. Psychiatry Research, 2008, 158, 19-25.	1.7	64
49	Molecular assessment of depression from mRNAs in the peripheral leukocytes. Annals of Medicine, 2008, 40, 336-342.	1.5	33
50	Altered HDAC5 and CREB mRNA expressions in the peripheral leukocytes of major depression. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2007, 31, 628-632.	2.5	87
51	Brief Assessment of Cognition in Schizophrenia: Validation of the Japanese version. Psychiatry and Clinical Neurosciences, 2007, 61, 602-609.	1.0	206
52	Proton magnetic resonance spectroscopy reveals an abnormality in the anterior cingulate of a subgroup of obsessive–compulsive disorder patients. Psychiatry Research - Neuroimaging, 2007, 154, 85-92.	0.9	38
53	Subjective and Objective Measures of Quality of Life Have Different Predictors for People with Schizophrenia. Psychological Reports, 2006, 99, 477-487.	0.9	34
54	Assessment of human stress and depression by DNA microarray analysis. Journal of Medical Investigation, 2005, 52, 266-271.	0.2	20

Tetsuro Ohmori

#	Article	IF	CITATIONS
55	Serotonin transporter mRNA expression in peripheral leukocytes of patients with major depression before and after treatment with paroxetine. Neuroscience Letters, 2005, 389, 12-16.	1.0	53
56	Schizophrenia Quality of Life Scale: validation of the Japanese version. Psychiatry Research, 2002, 113, 107-113.	1.7	60
57	Psychometric Properties of the Japanese Version of the Calgary Depression Scale for Schizophrenics. Journal of Nervous and Mental Disease, 2000, 188, 237-239.	0.5	25